FindTrial
Sign In

Observation and Study on Vitamin D3 for Immunotherapy of Refractory Graves Disease

Observation and Study on Vitamin D3 for Immunotherapy of Refractory Graves Disease

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000030587
Enrollment
Unknown
Registered
2020-03-08
Start date
2017-10-01
Completion date
Unknown
Last updated
2020-03-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Graves Hyperthyroidism

Interventions

A:Vitamin D3 1.5ug / d + methimazole 20mg / d
B :Vitamin D3 0.5ug / d + methimazole 20mg / d
C:methimazole 20mg / d

Sponsors

Yu Jing
Lead Sponsor

Eligibility

Sex/Gender
All
Age
23 Years to 44 Years

Inclusion criteria

Inclusion criteria: 1. Clinical features: diffuse goiter (confirmed by ultrasound), with or without exophthalmos, tachycardia, tremor, and sweating; 2. Laboratory diagnosis: decreased serum TSH levels, thyroid hormones, and Increased TRAb levels.

Exclusion criteria

Exclusion criteria: 1. Patients with cardiovascular, blood, nervous system, liver, kidney disease, active bone and joint disease, long-term use of hormones, alcohol, smoking, etc. are not allowed to enter the group; 2. thyroid cancer or other non-thyroid diseases but affect Patients whose functions are not allowed to enter the group; 3. Patients with other diseases who must take other drugs for a long time are not allowed to enter the group; 4. pregnant.

Design outcomes

Primary

MeasureTime frame
Thyroid function;Thyroid stimulating hormone receptor antibody;—

Countries

China

Contacts

Public ContactYu Jing

Department of Endocrinology, Chengdong Branch of the First Hospital of Quanzhou, Fujian

1045642615@qq.com+86 15159590252

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026